Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT1 | P04628 | 3/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | CLK2 | P49760 | 9/20 | 0.51 |
| ▸ | CLK3 | P49761 | 9/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.51 |
| ▸ | MAP3K8 | P41279 | 7/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4510663 | 0.94 | AURKA (0.51) | WNT1AURKAAURKBCLK2CLK3 | |
| SCHEMBL4493942 | 0.92 | AURKA (0.52) | WNT1AURKAAURKBCLK2CLK3 | |
| SCHEMBL4501508 | 0.89 | AURKA (0.50) | WNT1AURKAAURKBCLK2CLK3 | |
| SCHEMBL4492243 | 0.87 | CLK2 (0.52) | WNT1AURKAAURKBCLK2CLK3 | |
| SCHEMBL10700213 | 0.87 | AURKA (0.56) | AURKAAURKB | |
| SCHEMBL4507605 | 0.87 | AURKA (0.51) | WNT1AURKAAURKBCLK2CLK3 | |
| SCHEMBL4501171 | 0.86 | AURKA (0.49) | WNT1AURKAAURKBCLK2CLK3 | |
| SCHEMBL4509493 | 0.86 | AURKA (0.53) | WNT1AURKAAURKBCLK2CLK3 | |
| SCHEMBL4497835 | 0.86 | AURKA (0.51) | WNT1AURKAAURKBCLK2CLK3 | |
| SCHEMBL4504819 | 0.86 | AURKA (0.52) | WNT1AURKAAURKBMAP3K8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291968-A1 | SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | GEORGES GUY | 2009-11-26 | — | — | US | claimed |
| US-20090291968-A1 | SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | GEORGES GUY | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291968-A1 | SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | CYP3A43, CYP3A5, CYP3A7 | WNT1 1522/4885AURKA 1558/4885AURKB 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.